Wall Street analysts have given Halozyme Therapeutics a "Buy" rating, but there may be better short-term opportunities in the market. Wall Street legend Whitney Tilson says there's a huge new tech trend coming – and he's revealing his #1 pick for free. Some of MarketBeat's winning trading ideas this year have resulted in 5-15% weekly gains. Only 2.60% of the stock of Halozyme Therapeutics is held by insiders. Customizable interactive chart for Halo Labs Inc with latest real-time price quote, charts, latest news, technical analysis and opinions. Halozyme Therapeutics had a return on equity of 24.29% and a net margin of 10.78%. Include out of stock. Halozyme Therapeutics trades on the NASDAQ under the ticker symbol "HALO.". Halozyme Therapeutics' stock was trading at $18.22 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Shares of HALO can be purchased through any online brokerage account. The high price target for HALO is $60.00 and the low price target for HALO is $20.00. You may vote once every thirty days. View the latest Halozyme Therapeutics Inc. (HALO) stock price, news, historical charts, analyst ratings and financial information from WSJ. Company insiders that own Halozyme Therapeutics stock include Connie Matsui, Dimitrios Chondros, Helen Torley, James M Daly, Jeffrey William Henderson, Kenneth J Kelley and Michael J Labarre. Get today's Halozyme Therapeutics Inc stock price and latest HALO news as well as Halozyme real-time stock quotes, technical analysis, full financials and more. Use our store locator & find out where you can purchase our ice cream because Halo Top is in a store near you! Halozyme Therapeutics employs 132 workers across the globe. ), Halozyme Therapeutics has received 392 “underperform” votes. MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. 11 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Halozyme Therapeutics in the last year. 1 out of 5 & up & up. High institutional ownership can be a signal of strong market trust in this company. Halozyme Therapeutics, Inc. operates as a biopharma technology platform company in the United States, Switzerland, and internationally. Discover historical prices for HALO stock on Yahoo Finance. View our full suite of financial calendars and market data tables, all for free. It is based on a 60-month historical regression of the return on the stock onto the return on the S&P 500. Shop today to find Ice Cream & Frozen Dairy Desserts at incredible prices. View which stocks have been most impacted by COVID-19. Halo Platform Statistics. Halozyme Therapeutics has a market capitalization of $5.50 billion and generates $195.99 million in revenue each year. Get short term trading ideas from the MarketBeat Idea Engine. Halozyme Therapeutics, Inc. (HALO) stock is up 3.19% while the S&P 500 has fallen -1.63% as of 12:18 PM on Tuesday, Oct 20. 3 out of 5 & up & up. Price/Sales: Latest closing price divided by the last 12 months of revenue/sales per share. Since then, HALO shares have increased by 123.2% and is now trading at $40.66. Sale. Halozyme Therapeutics has a P/B Ratio of 55.70. Now it's being sold to one of the nation's biggest ice cream manufacturers, Wells Enterprises, owner of … Shop Target for Halo Top. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. HALO stock was purchased by a variety of institutional investors in the last quarter, including First Light Asset Management LLC, AJO LP, Morgan Stanley, Oak Ridge Investments LLC, WINTON GROUP Ltd, Wells Fargo & Company MN, Lateef Investment Management L.P., and Voloridge Investment Management LLC. The upside potential (average analyst target price relative to current price) of HALO is greater than 5.71% of all US stocks. halo stock price are also included in the list of such companies. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. HALO Stock Summary. Counsel, Chief Compliance Officer & Corp. Sec. Your health & safety is our priority, and we're taking COVID-19 very seriously. HALO is higher by $0.94 from the previous closing price of $29.46 on volume of 1,562,055 shares. Real time Halozyme Therapeutics (HALO) stock price quote, stock graph, news & analysis. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Company profile page for Eden Creamery LLC including stock price, company news, press releases, executives, board members, and contact information This is usually characteristic of DISTRIBUTION; however, price did not close below support. In addition, it is developing Tecentriq for non-small cell lung cancer; OCREVUS for multiple sclerosis; DARZALEX for the treatment of patients with amyloidosis, smoldering myeloma, and multiple myeloma; nivolumab for the treatment of solid tumors; ALXN1210 and ALXN1810 subcutaneous formulations; ARGX-113, a human neonatal Fc receptor; ARGX-117 to treat autoimmune diseases; and BMS-986179, an anti-CD-73 antibody. The company's success grew in 2016 after a GQ writer wrote an article about eating nothing but the ice … Halo Companies Inc (HALN) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global markets. Let's find out. Their forecasts range from $20.00 to $60.00. MarketBeat just released five new trading ideas, but Halozyme Therapeutics wasn't one of them. The biopharmaceutical company had revenue of $65.30 million for the quarter, compared to analysts' expectations of $59.35 million. HALO stock was sold by a variety of institutional investors in the last quarter, including State Street Corp, Third Security LLC, Fisher Asset Management LLC, Lombard Odier Asset Management Switzerland SA, Cubist Systematic Strategies LLC, WCM Investment Management LLC, Victory Capital Management Inc., and William Blair Investment Management LLC. Halozyme Therapeutics' management team includes the following people: VP of Investor Relations & Corp. Communications. Sr. VP, Gen. Do Not Sell My Information. Halozyme Therapeutics issued an update on its FY 2020 Among the technology companies in the top ten are Apple with an increase of 4,419 percent and Netflix with 2840 percent. Sign-up to receive the latest news and ratings for HALO and its competitors with MarketBeat's FREE daily newsletter. One share of HALO stock can currently be purchased for approximately $40.66. Earnings for Halozyme Therapeutics are expected to grow by 81.05% in the coming year, from $0.95 to $1.72 per share. This is a signs that BULLS are attempting to "absorb" supply. Halozyme Therapeutics has received 447 “outperform” votes. Halozyme Therapeutics has received a consensus rating of Buy. ... Price. Halozyme Therapeutics' stock is owned by a number of institutional and retail investors. All rights reserved. Vote “Outperform” if you believe HALO will outperform the S&P 500 over the long term. Halo Platform stock price is down by (-2.44%) today.USD worth of Halo Platform (HALO) has been traded in the past 24 hours. View insider buying and selling activity for Halozyme Therapeutics. The official website for Halozyme Therapeutics is www.halozyme.com. Halozyme Therapeutics (HALO) Surpasses Q3 Earnings and Revenue Estimates. (Add your “underperform” vote.). All Deals. Pre-Market earnings guidance on Monday, November, 23rd. View our earnings forecast for Halozyme Therapeutics. The company is also developing Perjeta for breast cancer; RITUXAN HYCELA and MabThera SC for the treatment of non-Hodgkin lymphoma and chronic lymphocytic leukemia (CLL); RITUXAN SC for patients with CLL; and HYQVIA for the treatment of immunodeficiency disorders. Sort by Featured. View all competitors. Earlier, the stock roared as much as 14.9% to an all-time high of 32.62. Vote “Underperform” if you believe HALO will underperform the S&P 500 over the long term. Find real-time HALO - Halozyme Therapeutics Inc stock quotes, ... Gilead (GILD) Reports Positive Top-Line Data on HIV Candidate. With a price/sales ratio of 27.25, Halozyme Therapeutics Inc has a higher such ratio than 92.94% of stocks in our set. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: You have already added five stocks to your watchlist. Its proprietary product include Hylenex recombinant, a formulation of rHuPH20 to facilitate subcutaneous fluid administration for achieving hydration; to enhance the dispersion and absorption of other injected drugs in subcutaneous urography; and to improve resorption of radiopaque agents. The biopharmaceutical company earns $-72,240,000.00 in net income (profit) each year or ($0.50) on an earnings per share basis. Specifically, they have bought $0.00 in company stock and sold $5,450,000.00 in company stock. Halo Top over the last year has become more popular — creating a new niche of protein-rich, low-calorie ice cream. Include out of stock. Buy halo stock price you can from brokers or on specialized sites. Halozyme (HALO) Q3 Earnings Top, 2020 View Up, Stock Rises Zacks Equity Research November 03, 2020 JNJ Quick Quote JNJ RHHBY Quick Quote RHHBY HALO Quick Quote HALO ARGX Quick Quote … 40.60 -0.06 (-0.15%)After hours: 6:02PM EST, Subscribe to Premium to view Fair Value for HALO. In the past three months, Halozyme Therapeutics insiders have sold more of their company's stock than they have bought. Experts have chosen 7 stocks out of 220 Zacks Rank #1 Strong Buys that have the highest potential to increase in price … How to buy halo stock price? View Halozyme Therapeutics' earnings history. This suggests that the stock has a possible downside of 14.1%. $0 – $15. View daily, weekly or … Halo Top ice cream became America's bestselling grocery store pint two years ago. Stock analysis for Halozyme Therapeutics Inc (HALO:NASDAQ GS) including stock price, stock chart, company news, key statistics, fundamentals and company profile.